Gilad Mamlok - Sol Gel Chief Officer
| SLGL Stock | USD 1.65 1.22 283.72% |
Executive
Mr. Gilad Mamlok is Chief Financial Officer of the Company. From August 2015 to January 2017, Mr. Mamlok served as the chief financial officer for Medigus Ltd., a medical device company dual listed on Nasdaq and the Tel Aviv Stock Exchange, or the TASE. From September 2005 to March 2015, Mr. Mamlok served as senior vice president, global finance and accounting of Given Imaging Ltd., a medical device company dual listed on Nasdaq and TASE, acquired by Covidien plc in February 2014. From January 2002 to September 2005, Mr. Mamlok served as chief financial officer of two other medical device companies since 2017.
| Age | 56 |
| Tenure | 7 years |
| Address | 7 Golda Meir Street, Ness Ziona, Israel, 7403650 |
| Phone | 972 8 931 3433 |
| Web | https://www.sol-gel.com |
Sol Gel Management Efficiency
The company has return on total asset (ROA) of (0.2163) % which means that it has lost $0.2163 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3585) %, meaning that it created substantial loss on money invested by shareholders. Sol Gel's management efficiency ratios could be used to measure how well Sol Gel manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.63. Return On Capital Employed is expected to rise to -0.68 this year. At this time, Sol Gel's Net Tangible Assets are quite stable compared to the past year. Non Current Assets Total is expected to rise to about 5.4 M this year, although the value of Other Assets will most likely fall to 0.95.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| CPA CFA | Janux Therapeutics | 48 | |
| Michelle MD | PepGen | 48 | |
| Hayley Parker | PepGen | N/A | |
| Minji MBA | Mineralys Therapeutics, Common | N/A | |
| Maria Dobek | Janux Therapeutics | 35 | |
| Ling Zhou | Adagene | N/A | |
| Dr MBA | Acrivon Therapeutics, Common | N/A | |
| Joshua JD | AN2 Therapeutics | 46 | |
| Erin OBoyle | Rezolute | N/A | |
| Susan Fischer | Aerovate Therapeutics | N/A | |
| Jeffrey Fellows | Mineralys Therapeutics, Common | N/A | |
| MS MBA | Rezolute | 50 | |
| Mary DeLena | PepGen | N/A | |
| Stefan Abele | Pharvaris BV | 54 | |
| Jennifer Huber | AN2 Therapeutics | N/A | |
| Mary JD | PepGen | 56 | |
| Michael Covarrubias | Rezolute | N/A | |
| James Pennington | Janux Therapeutics | N/A | |
| Katharine CPA | Acrivon Therapeutics, Common | N/A | |
| Cindy Berejikian | Mineralys Therapeutics, Common | N/A | |
| Stephen Yu | Aerovate Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.22 |
Sol Gel Technologies Leadership Team
Elected by the shareholders, the Sol Gel's board of directors comprises two types of representatives: Sol Gel inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sol. The board's role is to monitor Sol Gel's management team and ensure that shareholders' interests are well served. Sol Gel's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sol Gel's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tamar Jutkowitz, VP Counsel | ||
| Itzik Yosef, Vice President - Operations | ||
| Gilad Mamlok, Chief Officer | ||
| Alon SeriLevy, CEO, Co-Founder, Director | ||
| Karine Neimann, Vice President - Projects and Planning, Chief Chemist | ||
| Pr Avnir, CoFounder | ||
| Moshe Arkin, Executive Board | ||
| Eyal BenOr, Chief Officer |
Sol Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sol Gel a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (2.27) % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 19.22 M | ||||
| Shares Outstanding | 27.86 M | ||||
| Shares Owned By Insiders | 65.16 % | ||||
| Shares Owned By Institutions | 19.35 % | ||||
| Number Of Shares Shorted | 50.46 K | ||||
| Price To Earning | 11.16 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Sol Gel Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sol Gel. If investors know Sol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sol Gel listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.34) | Revenue Per Share 0.235 | Quarterly Revenue Growth 8.146 | Return On Assets (0.22) | Return On Equity (0.36) |
The market value of Sol Gel Technologies is measured differently than its book value, which is the value of Sol that is recorded on the company's balance sheet. Investors also form their own opinion of Sol Gel's value that differs from its market value or its book value, called intrinsic value, which is Sol Gel's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sol Gel's market value can be influenced by many factors that don't directly affect Sol Gel's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sol Gel's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sol Gel is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sol Gel's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.